A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505423-31-00

Acronym

MK-2870-015

Enrollment

115

Registered

2024-05-29

Start date

2024-08-08

Completion date

Unknown

Last updated

2025-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

Brief summary

Overall Survival (OS)

Detailed description

Progression-free Survival (PFS), Objective Response Rate (ORR), Duration of Response (DOR), Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Intervention Due to an AE

Interventions

DRUGPARACETAMOL

DRUG-

DRUGDOCETAXEL

DRUGTRIFLURIDINE

DRUGCOMBINATIONS

DRUGMK-2870

DRUGIRINOTECAN

DRUGPACLITAXEL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS)	—

Secondary

Measure	Time frame
Progression-free Survival (PFS), Objective Response Rate (ORR), Duration of Response (DOR), Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Intervention Due to an AE	—

Countries

Belgium, Denmark, France, Germany, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026